



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

February 2020





© 2020 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
608 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.cfenet.ubc.ca](http://www.cfenet.ubc.ca)  
Email: [info@cfenet.ubc.ca](mailto:info@cfenet.ubc.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





### TABLE OF CONTENTS

#### 1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

#### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

February 2020

N = 7342



Health Authority	Male	Female	All
FRASER	1426	436	1862
INTERIOR	409	95	504
NORTHERN	129	88	217
VANCOUVER COASTAL	3330	447	3777
VANCOUVER ISLAND	789	155	944
	<b>6083</b>	<b>1221</b>	<b>7304</b>
		<b>Unknown/not stated:</b>	<b>38</b>
		<b>Total:</b>	<b>7342</b>

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2015 - February 2020)






### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (February 2015 - February 2020)








### 1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (February 2015 - February 2020)






### 1.5 BC-CfE Enrollment: New Antiretroviral Participants (February 2015 - February 2020)






### 1.6 Percent Distribution of Active Participants by CD4 Count (February 2015 - February 2020)






1.7 Percent Distribution of Inactive Participants by CD4 Count  
(February 2015 - February 2020)






### 1.8 Active and Inactive Participants (February 2015 - February 2020)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (February 2015 - February 2020)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (February 2015 - February 2020)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(February 2015 - February 2020)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (February 2015 - February 2020)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(February 2015 - February 2020)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (February 2015 - February 2020)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(February 2015 - February 2020)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (February 2015 - February 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(February 2015 - February 2020)






1.18 Baseline CD4 for Antiretroviral First Starts (February 2015 - February 2020)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART  
(February 2015 - February 2020)**








### 1.20 Cumulative Resistance Testing Results by Resistance Category (February 2015 - February 2020)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (February 2015 - February 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	2	600	5	<40	3
1988	29	6	0	6	4	320	6	<40	3
1989	27	53	1	54	39	480	52	<40	3
1990	26	52	1	53	32	575	50	<40	3
1991	26	36	3	39	22	530	37	<40	3
1992	25	61	5	66	43	610	63	<40	3
1993	24	130	14	144	123	560	139	<40	3
1994	23	77	13	90	71	540	89	<40	3
1995	23	131	23	154	121	570	150	<40	3
1996	21	336	53	389	279	550	366	<40	3
1997	19	265	34	299	234	620	284	<40	3
1998	18	190	42	232	178	570	221	<40	3
1999	18	157	39	196	145	590	186	<40	3
2000	18	123	33	156	121	620	149	<40	3
2001	18	119	30	149	112	595	140	<40	3
2002	17	122	25	147	117	590	143	<40	3
2003	16	153	30	183	125	600	172	<40	3
2004	15	157	39	196	157	570	187	<40	3
2005	14	182	43	225	179	602	213	<40	3
2006	13	186	42	228	173	550	211	<40	3
2007	12	245	47	292	230	590	275	<40	3
2008	11	273	65	338	269	630	323	<40	3
2009	10	308	67	375	279	670	348	<40	3
2010	9	271	73	344	260	670	309	<40	3
2011	8	327	71	398	296	700	367	<40	3
2012	8	263	65	328	253	700	306	<40	3
2013	7	269	65	334	242	630	299	<40	3
2014	6	287	53	340	247	720	311	<40	3
2015	5	289	47	336	254	677	313	<40	3
2016	4	277	54	331	238	665	302	<40	3
2017	3	231	35	266	211	680	247	<40	3
2018	2	204	53	257	205	640	244	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	1	255	49	304	270	610	300	<40	3
2020	0	49	10	59	51	510	56	455	3
<b>Total:</b>		<b>6089</b>	<b>1224</b>	<b>7313</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7397	788	2456	<40	2145	610
FEB-2019	7377	798	1854	<40	1583	620
MAR-2019	7413	790	2085	<40	1752	610
APR-2019	7367	793	2142	<40	1747	610
MAY-2019	7428	792	2127	<40	1766	620
JUN-2019	7374	803	1926	<40	1593	611
JUL-2019	7385	811	2111	<40	1693	620
AUG-2019	7374	810	2107	<40	1621	600
SEP-2019	7352	806	2013	<40	1565	600
OCT-2019	7407	786	2141	<40	1739	620
NOV-2019	7354	781	2028	<40	1565	630
DEC-2019	7355	777	1701	<40	1266	610
JAN-2020	7372	775	2227	<40	1640	620
FEB-2020	7342	778	1882	<40	1329	630

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	1459	3449	73	73	65	350
FEB-2019	1490	3368	75	108	66	590
MAR-2019	1457	3509	74	636	61	400
APR-2019	1495	3414	80	<50	70	490
MAY-2019	1442	3655	78	87	69	450
JUN-2019	1501	3441	79	<40	71	550
JUL-2019	1488	3510	71	<40	58	530
AUG-2019	1510	3462	80	50	67	520
SEP-2019	1538	3337	94	<40	76	580
OCT-2019	1478	3647	80	120	68	470
NOV-2019	1498	3595	67	<40	55	560
DEC-2019	1483	3681	57	<40	47	480
JAN-2020	1457	3806	71	255	45	440
FEB-2020	1505	3645	72	<40	55	480

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	1459	14	20	191	160	34	13564
FEB-2019	7349	1490	7	16	160	181	-15	13593
MAR-2019	7372	1457	15	13	187	149	23	13613
APR-2019	7327	1495	10	15	152	181	-45	13641
MAY-2019	7391	1442	11	22	197	138	64	13684
JUN-2019	7334	1501	14	13	137	189	-57	13705
JUL-2019	7349	1488	13	13	181	163	15	13728
AUG-2019	7342	1510	12	18	169	176	-7	13764
SEP-2019	7317	1538	14	15	181	202	-25	13791
OCT-2019	7333	1478	3	13	222	148	16	13820
NOV-2019	7327	1498	9	17	163	168	-6	13853
DEC-2019	7326	1483	8	13	166	158	-1	13881
JAN-2020	7346	1457	8	12	182	154	20	13905
FEB-2020	7313	1505	11	18	140	177	-33	13940

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





**2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs**

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6803	486	53	<b>7397</b>	0.74%	91.97%	6.57%	0.72%	<b>100.00%</b>
FEB-2019	54	6782	492	49	<b>7377</b>	0.73%	91.93%	6.67%	0.66%	<b>100.00%</b>
MAR-2019	60	6813	490	50	<b>7413</b>	0.81%	91.91%	6.61%	0.67%	<b>100.00%</b>
APR-2019	57	6772	490	48	<b>7367</b>	0.77%	91.92%	6.65%	0.65%	<b>100.00%</b>
MAY-2019	55	6836	492	45	<b>7428</b>	0.74%	92.03%	6.62%	0.61%	<b>100.00%</b>
JUN-2019	57	6788	481	48	<b>7374</b>	0.77%	92.05%	6.52%	0.65%	<b>100.00%</b>
JUL-2019	61	6786	490	48	<b>7385</b>	0.83%	91.89%	6.64%	0.65%	<b>100.00%</b>
AUG-2019	60	6781	483	50	<b>7374</b>	0.81%	91.96%	6.55%	0.68%	<b>100.00%</b>
SEP-2019	57	6757	486	52	<b>7352</b>	0.78%	91.91%	6.61%	0.71%	<b>100.00%</b>
OCT-2019	60	6807	488	52	<b>7407</b>	0.81%	91.90%	6.59%	0.70%	<b>100.00%</b>
NOV-2019	59	6759	486	50	<b>7354</b>	0.80%	91.91%	6.61%	0.68%	<b>100.00%</b>
DEC-2019	61	6768	478	48	<b>7355</b>	0.83%	92.02%	6.50%	0.65%	<b>100.00%</b>
JAN-2020	60	6770	485	57	<b>7372</b>	0.81%	91.83%	6.58%	0.77%	<b>100.00%</b>
FEB-2020	60	6747	477	58	<b>7342</b>	0.82%	91.90%	6.50%	0.79%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)







**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3358 47%
FEB-2019	13 45%	3463 48%	12 41%	3262 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3308 46%
MAR-2019	6 30%	3474 48%	6 30%	3277 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3308 46%
APR-2019	12 43%	3473 48%	12 43%	3281 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3251 45%
MAY-2019	14 33%	3504 48%	14 33%	3312 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	24 57%	3265 45%
JUN-2019	3 14%	3485 49%	3 14%	3297 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	609 8%	16 76%	3207 45%
JUL-2019	8 36%	3510 49%	8 36%	3329 46%	0 0%	39 1%	0 0%	2 0%	0 0%	1 0%	1 5%	625 9%	13 59%	3187 44%
AUG-2019	14 39%	3516 49%	12 33%	3341 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	631 9%	20 56%	3150 44%
SEP-2019	5 19%	3497 49%	5 19%	3321 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 19%	656 9%	17 63%	3129 44%
OCT-2019	4 14%	3517 49%	2 7%	3335 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	671 9%	23 82%	3151 44%
NOV-2019	8 24%	3462 48%	7 21%	3285 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	730 10%	19 58%	3118 44%
DEC-2019	1 4%	3443 48%	1 4%	3265 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	14 50%	857 12%	13 46%	3056 43%
JAN-2020	3 13%	3411 47%	3 13%	3235 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 38%	1027 14%	12 50%	2966 41%
FEB-2020	3 9%	3359 47%	3 9%	3187 45%	0 0%	33 0%	0 0%	1 0%	0 0%	0 0%	15 43%	1169 16%	17 49%	2829 40%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)**

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3677	51%
MAR-2019	14	70%	3704	51%
APR-2019	16	57%	3667	51%
MAY-2019	28	67%	3694	51%
JUN-2019	18	86%	3653	51%
JUL-2019	14	64%	3660	51%
AUG-2019	22	61%	3633	51%
SEP-2019	22	81%	3633	51%
OCT-2019	24	86%	3675	51%
NOV-2019	25	76%	3678	51%
DEC-2019	27	96%	3720	52%
JAN-2020	21	88%	3769	52%
FEB-2020	32	91%	3786	53%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1070 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1487 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1027 39%	7 70%	1478 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1480 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1003 39%	9 100%	1466 57%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	983 38%	6 100%	1486 57%	0 0%	113 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	970 38%	11 92%	1461 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	955 37%	12 92%	1484 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	959 37%	13 93%	1494 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	941 37%	3 100%	1472 58%	0 0%	101 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	924 37%	7 100%	1467 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	912 37%	6 86%	1467 59%	1 14%	97 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
FEB-2020	0 0%	2 0%	1 14%	874 36%	6 86%	1451 60%	0 0%	97 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	6 100%	648 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	636 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	635 35%	0 0%	211 12%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	207 11%	0 0%	647 36%	0 0%	326 18%
SEP-2019	0 0%	1 0%	4 80%	610 35%	0 0%	209 12%	0 0%	622 35%	1 20%	325 18%
OCT-2019	0 0%	1 0%	6 60%	613 35%	1 10%	211 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	614 37%	0 0%	209 12%	1 14%	525 31%	1 14%	326 19%
DEC-2019	0 0%	1 0%	3 100%	608 37%	0 0%	203 12%	0 0%	513 31%	0 0%	325 20%
JAN-2020	0 0%	1 0%	2 100%	589 36%	0 0%	202 12%	0 0%	502 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	559 36%	0 0%	198 13%	0 0%	484 31%	0 0%	320 21%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2436 63%	5 23%	726 19%	0 0%	40 1%	1 5%	652 17%
MAR-2019	0 0%	27 1%	8 62%	2482 64%	5 38%	746 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2496 64%	3 21%	739 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2560 64%	6 21%	748 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	10 77%	2562 65%	3 23%	745 19%	0 0%	37 1%	0 0%	625 16%
JUL-2019	0 0%	27 1%	13 81%	2608 65%	3 19%	757 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2649 65%	1 4%	756 19%	0 0%	36 1%	3 11%	627 15%
SEP-2019	0 0%	28 1%	7 47%	2653 65%	6 40%	758 19%	0 0%	37 1%	2 13%	630 15%
OCT-2019	0 0%	28 1%	13 87%	2723 66%	1 7%	758 18%	0 0%	34 1%	1 7%	631 15%
NOV-2019	3 13%	88 2%	16 70%	2746 65%	4 17%	771 18%	0 0%	33 1%	0 0%	623 15%
DEC-2019	13 65%	231 5%	6 30%	2724 64%	1 5%	745 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 47%	423 10%	8 42%	2696 62%	0 0%	707 16%	0 0%	32 1%	2 11%	595 14%
FEB-2020	13 50%	603 14%	11 42%	2650 60%	2 8%	654 15%	0 0%	29 1%	0 0%	578 13%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1833	24.78	1481	20.02	3061	41.38	100	1.35	53	0.72	869	11.75
FEB-2019	1804	24.45	1479	20.05	3076	41.70	99	1.34	49	0.66	870	11.79
MAR-2019	1794	24.20	1473	19.87	3127	42.18	98	1.32	50	0.67	871	11.75
APR-2019	1760	23.89	1461	19.83	3140	42.62	100	1.36	48	0.65	858	11.65
MAY-2019	1774	23.88	1450	19.52	3204	43.13	97	1.31	45	0.61	858	11.55
JUN-2019	1743	23.64	1441	19.54	3204	43.45	95	1.29	48	0.65	843	11.43
JUL-2019	1717	23.25	1429	19.35	3242	43.90	92	1.25	48	0.65	857	11.60
AUG-2019	1688	22.89	1403	19.03	3297	44.71	94	1.27	50	0.68	842	11.42
SEP-2019	1699	23.11	1364	18.55	3304	44.94	93	1.26	52	0.71	840	11.43
OCT-2019	1707	23.05	1344	18.14	3364	45.42	93	1.26	52	0.70	847	11.44
NOV-2019	1669	22.70	1274	17.32	3431	46.65	91	1.24	50	0.68	839	11.41
DEC-2019	1644	22.35	1250	17.00	3493	47.49	92	1.25	48	0.65	828	11.26
JAN-2020	1620	21.98	1208	16.39	3573	48.47	87	1.18	57	0.77	827	11.22
FEB-2020	1574	21.44	1155	15.73	3653	49.75	85	1.16	58	0.79	817	11.13

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	22	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	13	0	2	5	2	4	300
JAN-2020	12	0	2	1	4	4	490
FEB-2020	18	5	1	4	3	5	330

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start







**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12253	3831
FEB-2019	12261	3830
MAR-2019	12291	3860
APR-2019	12318	3884
MAY-2019	12334	3885
JUN-2019	12334	3890
JUL-2019	12351	3905
AUG-2019	12383	3922
SEP-2019	12402	3940
OCT-2019	12436	3964
NOV-2019	12458	3973
DEC-2019	12482	3987
JAN-2020	12546	4040
FEB-2020	12591	4071

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved  
**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants  
February 2020

N = 7342

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2020

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

February 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	9	10	*
	50+	28	40	*
	<b>Total HSDA:</b>	<b>43</b>	<b>56</b>	<b>29</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>74</b>	<b>98</b>	<b>53</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>363</b>	<b>494</b>	<b>276</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	14
	35-49	*	*	53
	50+	*	*	79
<b>Total HSDA:</b>	<b>192</b>	<b>263</b>	<b>146</b>	
<b>Total HA:</b>		<b>672</b>	<b>911</b>	<b>504</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	61	62	*
	35-49	176	197	*
	50+	430	647	*
<b>Total HA:</b>		<b>672</b>	<b>911</b>	<b>504</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	537	728	409
Female	135	183	95

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	504	55	610	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)







**4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration  
INTERIOR Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	20	12
	5 years or more	10	6
	<5 years	13	11
	<b>Total HSDA:</b>	<b>43</b>	<b>29</b>
KOOTENAY BOUNDARY	10 years or more	45	31
	5 years or more	16	11
	<5 years	13	11
	<b>Total HSDA:</b>	<b>74</b>	<b>53</b>
OKANAGAN	10 years or more	225	161
	5 years or more	73	59
	<5 years	65	56
	<b>Total HSDA:</b>	<b>363</b>	<b>276</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	106	77
	5 years or more	46	40
	<5 years	40	29
	<b>Total HSDA:</b>	<b>192</b>	<b>146</b>
<b>Total HA:</b>		<b>672</b>	<b>504</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	396	281
	5 years or more	145	116
	<5 years	131	107
<b>Total HA:</b>		<b>672</b>	<b>504</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	45	64	15	26
KOOTENAY BOUNDARY	76	123	26	45
OKANAGAN	226	928	60	284
THOMPSON/CARIBOO/SHUSWAP	138	517	39	143
<b>Total:</b>	<b>485</b>	<b>1632</b>	<b>140</b>	<b>498</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
<b>Total:</b>	<b>89</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	6	6	6
	20-34	30	32	21
	35-49	102	112	77
	50+	236	311	182
	<b>Total HSDA:</b>		<b>374</b>	<b>461</b>
FRASER NORTH	0-19	7	7	*
	20-34	117	117	*
	35-49	341	369	*
	50+	568	895	*
	<b>Total HSDA:</b>		<b>1033</b>	<b>1388</b>
FRASER SOUTH	0-19	7	7	6
	20-34	113	115	83
	35-49	332	378	270
	50+	552	812	445
	<b>Total HSDA:</b>		<b>1004</b>	<b>1312</b>
<b>Total HA:</b>		<b>2411</b>	<b>3161</b>	<b>1862</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	20	20	14
	20-34	260	264	180
	35-49	775	859	601
	50+	1356	2018	1067
<b>Total HA:</b>		<b>2411</b>	<b>3161</b>	<b>1862</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1828	2420	1426
Female	583	741	436

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	1862	52	630	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





#### 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	223	170
	5 years or more	72	58
	<5 years	79	58
	<b>Total HSDA:</b>	<b>374</b>	<b>286</b>
FRASER NORTH	10 years or more	578	412
	5 years or more	250	195
	<5 years	205	165
	<b>Total HSDA:</b>	<b>1033</b>	<b>772</b>
FRASER SOUTH	10 years or more	564	444
	5 years or more	227	171
	<5 years	213	189
	<b>Total HSDA:</b>	<b>1004</b>	<b>804</b>
<b>Total HA:</b>		<b>2411</b>	<b>1862</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1365	1026
	5 years or more	549	424
	<5 years	497	412
<b>Total HA:</b>		<b>2411</b>	<b>1862</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	146	495	31	55
FRASER NORTH	257	1577	52	236
FRASER SOUTH	223	1486	50	456
<b>Total:</b>	<b>626</b>	<b>3558</b>	<b>133</b>	<b>747</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	197
FRASER NORTH	638
FRASER SOUTH	497
<b>Total:</b>	<b>1332</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>344</b>	<b>494</b>
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>176</b>	<b>225</b>
VANCOUVER	0-19	26	26	7
	20-34	443	458	310
	35-49	1368	1542	964
	50+	2843	4857	2069
	<b>Total HSDA:</b>	<b>4680</b>	<b>6883</b>	<b>3350</b>
<b>Total HA:</b>		<b>5200</b>	<b>7602</b>	<b>3777</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	30	30	9
	20-34	500	516	355
	35-49	1491	1677	1060
	50+	3179	5379	2353
<b>Total HA:</b>		<b>5200</b>	<b>7602</b>	<b>3777</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4596	6679	3330
Female	602	921	447

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3777	54	640	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration  
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	188	152
	5 years or more	89	75
	<5 years	67	64
	<b>Total HSDA:</b>	<b>344</b>	<b>291</b>
RICHMOND	10 years or more	102	73
	5 years or more	37	31
	<5 years	37	32
	<b>Total HSDA:</b>	<b>176</b>	<b>136</b>
VANCOUVER	10 years or more	2802	1921
	5 years or more	1130	822
	<5 years	748	607
	<b>Total HSDA:</b>	<b>4680</b>	<b>3350</b>
<b>Total HA:</b>		<b>5200</b>	<b>3777</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3092	2146
5 years or more	1256	928
<5 years	852	703
<b>Total HA:</b>	<b>5200</b>	<b>3777</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	182	500	60	176
RICHMOND	44	289	12	94
VANCOUVER	641	10893	219	5242
<b>Total:</b>	<b>867</b>	<b>11682</b>	<b>291</b>	<b>5512</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	8
RICHMOND	5
VANCOUVER	110
<b>Total:</b>	<b>123</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA







**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>331</b>	<b>466</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>127</b>	<b>169</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	56
	35-49	*	*	147
	50+	*	*	375
	<b>Total HSDA:</b>		<b>750</b>	<b>1057</b>
<b>Total HA:</b>		<b>1208</b>	<b>1692</b>	<b>944</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>1208</b>	<b>1692</b>	<b>944</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	998	1395	789
Female	210	297	155

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	944	55	570	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	181	142
	5 years or more	74	60
	<5 years	76	58
	<b>Total HSDA:</b>	<b>331</b>	<b>260</b>
NORTH VANCOUVER ISLAND	10 years or more	73	60
	5 years or more	34	28
	<5 years	20	18
	<b>Total HSDA:</b>	<b>127</b>	<b>106</b>
SOUTH VANCOUVER ISLAND	10 years or more	439	317
	5 years or more	157	133
	<5 years	154	128
	<b>Total HSDA:</b>	<b>750</b>	<b>578</b>
<b>Total HA:</b>		<b>1208</b>	<b>944</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	693	519
	5 years or more	265	221
	<5 years	250	204
<b>Total HA:</b>		<b>1208</b>	<b>944</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	204	870	82	200
NORTH VANCOUVER ISLAND	151	268	51	80
SOUTH VANCOUVER ISLAND	218	1801	44	563
<b>Total:</b>	<b>573</b>	<b>2939</b>	<b>177</b>	<b>843</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	50
NORTH VANCOUVER ISLAND	40
SOUTH VANCOUVER ISLAND	112
<b>Total:</b>	<b>202</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>41</b>	<b>49</b>
NORTH WEST	20-34	11	12	7
	35-49	17	33	15
	50+	41	64	34
	<b>Total HSDA:</b>	<b>69</b>	<b>109</b>	<b>56</b>
NORTHERN INTERIOR	0-19	5	5	*
	20-34	22	23	*
	35-49	72	91	*
	50+	89	152	*
	<b>Total HSDA:</b>	<b>188</b>	<b>271</b>	<b>136</b>
<b>Total HA:</b>		<b>298</b>	<b>429</b>	<b>217</b>

Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
0-19	6	6	*
20-34	36	38	*
35-49	108	146	*
50+	148	239	*
<b>Total HA:</b>	<b>298</b>	<b>429</b>	<b>217</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	180	264	129
Female	118	165	88

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	217	50	540	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	*
	5 years or more	14	*
	<5 years	6	*
	<b>Total HSDA:</b>	<b>41</b>	<b>25</b>
NORTH WEST	10 years or more	35	27
	5 years or more	21	18
	<5 years	13	11
	<b>Total HSDA:</b>	<b>69</b>	<b>56</b>
NORTHERN INTERIOR	10 years or more	77	54
	5 years or more	62	48
	<5 years	49	34
	<b>Total HSDA:</b>	<b>188</b>	<b>136</b>
<b>Total HA:</b>		<b>298</b>	<b>217</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	133	92
	5 years or more	97	76
	<5 years	68	49
<b>Total HA:</b>		<b>298</b>	<b>217</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	43	64	8	9
NORTH WEST	82	164	18	33
NORTHERN INTERIOR	116	468	19	182
<b>Total:</b>	<b>241</b>	<b>696</b>	<b>45</b>	<b>224</b>

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	7
NORTH WEST	19
NORTHERN INTERIOR	13
<b>Total:</b>	<b>39</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Physician out of HA** is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





### 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	24	40	15
	THOMPSON/CARIBOO/SHUSWAP	24	45	19
	<b>Total HA:</b>	<b>60</b>	<b>104</b>	<b>45</b>
FRASER	FRASER EAST	38	48	30
	FRASER NORTH	53	89	43
	FRASER SOUTH	77	110	58
	<b>Total HA:</b>	<b>168</b>	<b>247</b>	<b>131</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	26	49	24
	RICHMOND	9	14	7
	VANCOUVER	482	856	368
	<b>Total HA:</b>	<b>517</b>	<b>919</b>	<b>399</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	52	81	42
	NORTH VANCOUVER ISLAND	19	28	17
	SOUTH VANCOUVER ISLAND	38	82	32
	<b>Total HA:</b>	<b>109</b>	<b>191</b>	<b>91</b>
NORTHERN	NORTH EAST	11	13	9
	NORTH WEST	27	58	24
	NORTHERN INTERIOR	71	110	57
	<b>Total HA:</b>	<b>109</b>	<b>181</b>	<b>90</b>
<b>Total:</b>		<b>963</b>	<b>1642</b>	<b>756</b>

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	604	1046	472
Female	359	596	284

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	756	52	480	35

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir (Ziagen, ABC):** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Amphotericin B (Fungilin):** a drug used for treatment of candidiasis and other fungal infections.

**Amprenavir (Agenerase, APV):** a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

**Antiretroviral (ARV):** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz, ATV):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla (ATP):** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Combivir (CBV):** the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

**Complera (CPL):** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista, DRV):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.







## Monthly Report

**Descovy (DSC):** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

**Didanosine (Videx, DDI):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay, DTG):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz, EFV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir (EGV):** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine (FTC):** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon, T20):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intelence, ETV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Ethambutol (Myambutol):** an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir, fAPV):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya (GNV):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Granulocyte Colony Stimulating Factor (GCSF, Neupogen):** a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa (KIV):** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine (3TC):** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra, LPV/r):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





## Monthly Report

**Maraviroc (Celsentri, MVC):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Moxifloxacin:** a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept, NFV):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune, NVP):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**NRTI:** see NUCLEOSIDE ANALOG.

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Octreotide Acetate (Sandostatin):** a drug used to treat chronic refractory diarrhea.

**Odefsey (ODF):** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Paromomycin (Humatin):** an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





## Monthly Report

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix (PZC):** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

**Raltegravir (RGV, Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant, RPV):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir, RTV):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Saquinavir (Invirase, SQV):** a PROTEASE INHIBITOR from Hoffman-La Roche.

**Stavudine (Zerit, d4T):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild (STR):** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus, TPV):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq (TRQ):** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir (TRZ):** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada (TRU):** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





## Monthly Report

---

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir, AZT):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

